{"public_id":"cl_f357cbb949a94515721f7044d95680ef","status":"active","superseded_by_public_id":null,"corpus_id":10565127,"text":"The 500-mg gefitinib dose caused transient acne-like rash and diarrhea more frequently than the 250-mg dose.","confidence":0.95,"paper":{"corpus_id":10565127,"title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.","url":"https://sah.borca.ai/papers/10565127"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_31f64114a66927bedb27f15434a6fc04","name":"acne-like rash","description":"A transient skin adverse event reported with gefitinib treatment.","types":["adverse event"],"url":"https://sah.borca.ai/concepts/co_31f64114a66927bedb27f15434a6fc04"},{"public_id":"co_80433368bdb51844e2f0c7b4b44600f5","name":"diarrhea","description":"A gastrointestinal adverse event reported with gefitinib treatment.","types":["adverse event"],"url":"https://sah.borca.ai/concepts/co_80433368bdb51844e2f0c7b4b44600f5"},{"public_id":"co_e76c6e58565611c4ec460101f3b24694","name":"500-mg gefitinib dose","description":"The higher daily oral gefitinib dose tested in the randomized trial.","types":["intervention dose"],"url":"https://sah.borca.ai/concepts/co_e76c6e58565611c4ec460101f3b24694"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_f357cbb949a94515721f7044d95680ef"}